Achmea Investment Management B.V. Has $1.19 Million Stock Position in Agilent Technologies, Inc. (NYSE:A)

Achmea Investment Management B.V. reduced its position in Agilent Technologies, Inc. (NYSE:A - Free Report) by 26.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 8,887 shares of the medical research company's stock after selling 3,125 shares during the period. Achmea Investment Management B.V.'s holdings in Agilent Technologies were worth $1,194,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of A. CKW Financial Group lifted its holdings in shares of Agilent Technologies by 114.9% during the 4th quarter. CKW Financial Group now owns 187 shares of the medical research company's stock worth $25,000 after acquiring an additional 100 shares during the period. Global X Japan Co. Ltd. increased its position in Agilent Technologies by 161.1% during the fourth quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company's stock worth $25,000 after purchasing an additional 116 shares during the last quarter. Hanson & Doremus Investment Management raised its stake in Agilent Technologies by 66.5% during the fourth quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company's stock worth $35,000 after purchasing an additional 105 shares during the period. OFI Invest Asset Management acquired a new position in shares of Agilent Technologies in the 4th quarter valued at $37,000. Finally, RPg Family Wealth Advisory LLC purchased a new stake in shares of Agilent Technologies during the 3rd quarter valued at $38,000.

Agilent Technologies Stock Performance

Shares of NYSE:A traded down $0.83 during trading on Wednesday, hitting $122.27. 1,405,863 shares of the company traded hands, compared to its average volume of 1,678,213. The stock has a market capitalization of $34.86 billion, a price-to-earnings ratio of 28.11, a PEG ratio of 3.44 and a beta of 1.11. Agilent Technologies, Inc. has a one year low of $117.17 and a one year high of $155.35. The company has a quick ratio of 1.66, a current ratio of 2.20 and a debt-to-equity ratio of 0.56. The business's fifty day moving average is $137.70 and its 200-day moving average is $137.68.

Remove Ads

Agilent Technologies (NYSE:A - Get Free Report) last issued its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.04. The firm had revenue of $1.68 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. As a group, equities analysts predict that Agilent Technologies, Inc. will post 5.57 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st will be given a dividend of $0.248 per share. The ex-dividend date is Tuesday, April 1st. This represents a $0.99 annualized dividend and a dividend yield of 0.81%. Agilent Technologies's dividend payout ratio is presently 22.76%.

Analyst Ratings Changes

A has been the topic of several research reports. Sanford C. Bernstein cut their target price on Agilent Technologies from $140.00 to $135.00 and set a "market perform" rating on the stock in a research report on Tuesday, November 26th. Wells Fargo & Company cut their price objective on Agilent Technologies from $157.00 to $155.00 and set an "overweight" rating on the stock in a report on Monday, December 9th. StockNews.com raised Agilent Technologies from a "hold" rating to a "buy" rating in a research note on Tuesday, December 24th. Barclays raised shares of Agilent Technologies from an "underweight" rating to an "equal weight" rating and increased their target price for the stock from $135.00 to $145.00 in a research report on Monday, February 10th. Finally, Bank of America reduced their price target on shares of Agilent Technologies from $153.00 to $150.00 and set a "neutral" rating on the stock in a research report on Friday, December 13th. Seven analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Agilent Technologies presently has an average rating of "Moderate Buy" and a consensus target price of $146.15.

Insider Buying and Selling

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of the company's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total value of $286,650.00. Following the completion of the sale, the chief executive officer now directly owns 39,652 shares in the company, valued at $5,947,800. This represents a 4.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Rodney Gonsalves sold 1,908 shares of Agilent Technologies stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $121.98, for a total value of $232,737.84. Following the transaction, the vice president now directly owns 21,786 shares in the company, valued at approximately $2,657,456.28. The trade was a 8.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.